<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aspirin-exacerbated respiratory disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aspirin-exacerbated respiratory disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Aspirin-exacerbated respiratory disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tanya M Laidlaw, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elliot Israel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Corren, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Aspirin-exacerbated respiratory disease (AERD), which is commonly called nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD) in Europe, refers to the combination of asthma, chronic rhinosinusitis (CRS) with nasal polyposis, and NSAID intolerance. NSAID intolerance presents as acute upper and/or lower respiratory tract symptoms following the ingestion of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (acetylsalicylic acid [ASA]) or other cyclooxygenase 1 (COX-1)-inhibiting NSAIDs.</p><p>The first case of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> sensitivity in a patient with asthma was described in 1902, a few years after the introduction of aspirin into clinical use. In 1968, Samter and Beers described a triad consisting of asthma, aspirin sensitivity, and nasal polyps [<a href="#rid1">1</a>], which came to be known as Samter's triad. The modern name for this triad is AERD.</p><p>An overview of AERD with emphasis on pathophysiology and the management of asthma will be presented here. Other types of hypersensitivity reactions to NSAIDs and the treatment of CRS with nasal polyposis are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2085.html" rel="external">"Diagnostic challenge and desensitization protocols for NSAID reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H347427673"><span class="h1">TERMINOLOGY</span></p><p class="headingAnchor" id="H347427733"><span class="h2">NSAIDs</span><span class="headingEndMark"> — </span>The primary effect of nonsteroidal anti-inflammatory drugs (NSAIDs) is to inhibit cyclooxygenase (COX; also called prostaglandin synthase), thereby impairing the transformation of arachidonic acid (AA) to prostaglandins, prostacyclin, and thromboxanes and enhancing production of leukotrienes  (<a class="graphic graphic_figure graphicRef76922" href="/z/d/graphic/76922.html" rel="external">figure 1</a>). Two related isoforms of the COX enzyme have been described, COX-1 and COX-2. Some NSAIDs have a greater inhibitory effect on COX-1 and others on COX-2  (<a class="graphic graphic_table graphicRef62880" href="/z/d/graphic/62880.html" rel="external">table 1</a>). COX-1 inhibition is the stimulus for acute reactions to NSAIDs in aspirin-exacerbated respiratory disease (AERD). In this topic review, the term "NSAID" includes <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (acetylsalicylic acid [ASA]). However, in some clearly marked sections, aspirin is discussed exclusive of other NSAIDs.</p><p class="headingAnchor" id="H347427727"><span class="h2">AERD</span><span class="headingEndMark"> — </span>Aspirin-exacerbated respiratory disease refers to the combination of:</p><p class="bulletIndent1"><span class="glyph">●</span>Asthma</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic rhinosinusitis (CRS) with nasal polyposis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reactions to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and other COX-1-inhibiting NSAIDs, in which symptoms of nasal congestion and bronchoconstriction typically begin 20 minutes to 3 hours after administration</p><p></p><p>Patients with AERD are also described as having aspirin-sensitive asthma or aspirin-intolerant asthma, although these terms refer to just one component of the disorder. The term "AERD" places emphasis on the chronic upper and lower respiratory disease as the fundamental disorder and a reaction to NSAIDs as an exacerbating factor [<a href="#rid2">2,3</a>]. Because NSAID exposure is not the cause of the disorder, avoidance of NSAIDs by these patients does not result in resolution of asthma or CRS.</p><p class="headingAnchor" id="H2"><span class="h2">Pseudoallergy</span><span class="headingEndMark"> — </span>Reactions to NSAIDs in patients with AERD are classified as "pseudoallergic" because they are not immunoglobulin E (IgE)-mediated. These reactions represent an abnormal biochemical response to the pharmacologic actions of NSAIDs. In contrast, IgE-mediated "allergic" reactions result from the formation of antibodies against a specific drug, haptenated drug, or a group of structurally similar drugs. Pseudoallergic reactions are triggered by a wide range of structurally distinct NSAIDs that have in common the ability to inhibit the COX-1 enzyme.</p><p>Reactions to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in patients with AERD are characterized as type 1 pseudoallergic reactions. The other types of pseudoallergic reactions to NSAIDs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions", section on 'Pseudoallergic reactions'</a>.)</p><p class="headingAnchor" id="H3092412260"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Fully developed AERD (asthma, polyposis, and nonsteroidal anti-inflammatory drug [NSAID] sensitivity) is usually diagnosed in adults. It is rare in children and adolescents [<a href="#rid4">4</a>]. The three component disorders of AERD tend to develop serially over a period of years, although some patients may present with rapid progression of sinonasal symptoms to asthma [<a href="#rid2">2,5</a>]. Many patients report a history of progressive rhinosinusitis, which gradually worsens and begins to involve inflammation in the lower airway. The diagnosis of asthma then follows, although, in some series, asthma was the first component to be diagnosed [<a href="#rid6">6</a>]. At some point during this progression, nasal polyposis and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>/NSAID sensitivity appears, although the latter may not be recognized if the patient rarely takes NSAIDs.</p><p>The prevalence of AERD is approximately 7 percent among adults with asthma, based on a 2014 metaanalysis of clinical trial data [<a href="#rid7">7</a>]. Among patients with severe asthma, the prevalence is twice as high, at approximately 14 percent. Among patients with chronic rhinosinusitis (CRS) with nasal polyposis, the prevalence is about 16 percent [<a href="#rid8">8</a>]. However, some patients may not be aware that they are sensitive to NSAIDs. In a prospective study of 80 adults presenting consecutively to an allergy and immunology clinic with CRS and nasal polyps, 36 percent reported sensitivity to NSAIDs, but 49 percent reacted to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> upon challenge [<a href="#rid9">9</a>].</p><p>The asthma and chronic sinusitis of AERD usually become more severe over time, even with NSAID avoidance [<a href="#rid3">3,10-12</a>]. However, not all patients have severe asthma, and, for many patients, the symptoms related to nasal polyposis and CRS are more troubling on a day-to-day basis [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathophysiology of AERD is not fully understood. There appears to be a dysregulation of arachidonic acid (AA) metabolism, particularly with an overproduction of leukotrienes, which may result from decreased inhibition of the 5-lipoxygenase (5-LO) pathway of AA metabolism by prostaglandin E<sub>2</sub> (PGE<sub>2</sub>). The overproduction of leukotrienes is further exacerbated by the action of cyclooxygenase 1 (COX-1) inhibitors (which block production of PGE<sub>2</sub>). In addition, patients with AERD may have decreased elaboration of downregulatory fatty acid products, such as lipoxins. Collectively, these abnormalities result in an imbalance between proinflammatory and anti-inflammatory mediators.</p><p class="headingAnchor" id="H7"><span class="h2">Normal arachidonic acid metabolism</span><span class="headingEndMark"> — </span>AA is derived from the membrane phospholipids of many cell types and is metabolized along different pathways to yield various lipid mediators. Some of these mediators are proinflammatory and some are anti-inflammatory. A few can act in both capacities, depending upon the target cell. A simplified overview of AA metabolism is provided  (<a class="graphic graphic_figure graphicRef50924" href="/z/d/graphic/50924.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H8"><span class="h3">5-lipoxygenase pathway</span><span class="headingEndMark"> — </span>The metabolism of AA by the enzyme 5-LO generates the leukotrienes (LTs), as depicted in the figure  (<a class="graphic graphic_figure graphicRef50924" href="/z/d/graphic/50924.html" rel="external">figure 2</a>). The cysteinyl leukotrienes (cysLTs), LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>, are potent inducers of bronchoconstriction, mucus secretion, nasal mucosal swelling, and airway edema and also attract eosinophils into the airways [<a href="#rid13">13-15</a>]. These are the major LTs synthesized by eosinophils and mast cells, cell types that are abundant in inflamed airways.</p><p>Leukotriene B<sub>4</sub> (a non-cysLT) is also proinflammatory but with effects on neutrophils and monocytes. Yet another 5-LO product, 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE), is a very potent eosinophil chemoattractant  (<a class="graphic graphic_figure graphicRef50924" href="/z/d/graphic/50924.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H9"><span class="h3">Cyclooxygenase pathway</span><span class="headingEndMark"> — </span>The metabolism of AA by the two cyclooxygenase isoforms (COX-1 and COX-2, also known as cycloendoperoxidase H synthases or prostaglandin synthases) yields prostaglandins and thromboxanes  (<a class="graphic graphic_figure graphicRef76922" href="/z/d/graphic/76922.html" rel="external">figure 1</a>) [<a href="#rid16">16</a>]. One of the prostaglandins, prostaglandin D<sub>2</sub> (PGD<sub>2</sub>), is predominantly produced by mast cells and has a bronchoconstrictor effect. Production of PGD<sub>2</sub> and its metabolite, PGD<sub>2</sub>S, is relatively <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> resistant and may be more dependent upon COX-2 than COX-1. In contrast, PGE<sub>2</sub> is a bronchodilator with potent anti-inflammatory effects. It is expressed in a broad range of cells and is decreased after COX-1 inhibition [<a href="#rid16">16-18</a>]. PGE<sub>2</sub> is believed to act as a "brake" on the production of the proinflammatory LTs. (See  <a class="medical medical_review" href="/z/d/html/7989.html" rel="external">"NSAIDs (including aspirin): Pharmacology and mechanism of action"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Abnormalities in AERD</span><span class="headingEndMark"> — </span>Studies of patients with AERD demonstrate a baseline dysregulation of AA metabolism with greatly increased production of the proinflammatory and underproduction of the anti-inflammatory products compared with patients with asthma but without AERD [<a href="#rid19">19-23</a>]. The proinflammatory leukotrienes promote airway inflammation and edema. The baseline dysregulation is acutely exaggerated by ingestion of COX-1 inhibitors, perhaps because the synthesis of PGE<sub>2</sub> is reduced and the "brake" on leukotrienes is released [<a href="#rid24">24-27</a>]. While mast cells have traditionally been thought to be the major source of cysLTs, accumulating evidence suggests that platelets may play a role in this process by providing the enzymes needed for leukocytes to produce leukotrienes [<a href="#rid28">28,29</a>].</p><p>The following abnormalities, which support this model of AERD pathophysiology, have been identified in patients with AERD [<a href="#rid30">30-41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The primary cellular source of leukotriene LTC<sub>4</sub> in patients with AERD appears to be mast cells in the nasal polyp tissue and bronchi, although eosinophils are also capable of producing large amounts [<a href="#rid32">32,42</a>]. Both cell types are increased and activated in the respiratory tracts of patients with AERD [<a href="#rid33">33-35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The enzyme LTC<sub>4</sub> synthase, which mediates the formation of LTC<sub>4</sub>, is overexpressed by eosinophils and other leukocytes in both nasal and pulmonary tissues of some patients with AERD  (<a class="graphic graphic_figure graphicRef50924" href="/z/d/graphic/50924.html" rel="external">figure 2</a>) [<a href="#rid33">33,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal aggregations of platelets and leukocytes (specifically, neutrophils, eosinophils, and monocytes) were demonstrated in nasal polyp tissue and peripheral blood from patients with AERD [<a href="#rid28">28</a>]. When closely associated, platelets and leukocytes can share metabolic processes (ie, transcellular synthesis) to produce enhanced amounts of proinflammatory leukotrienes. In patients with AERD, the percentages of platelet-leukocyte aggregates correlated with markers of systemic cysLT production, suggesting that these aggregates play a role in the enhanced production of leukotrienes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytes in the nasal mucosa of patients with AERD overexpress cysteinyl leukotriene receptor type 1, one of two known receptors for cysLTs  (<a class="graphic graphic_figure graphicRef75064" href="/z/d/graphic/75064.html" rel="external">figure 3</a>) [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications that inhibit leukotriene synthesis or antagonize leukotriene receptors (eg, <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a>, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>) blunt or occasionally block the bronchoconstrictive response to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid15">15,43-45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PGD<sub>2</sub> appears to be overproduced at baseline in AERD and further increased after <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge [<a href="#rid16">16,17,46,47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Levels of PGE<sub>2</sub> in polyp tissue and lower airway fibroblasts of AERD patients are reduced at baseline and fall further after <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge [<a href="#rid48">48-50</a>]. PGE<sub>2</sub> is believed to act as a brake on leukotriene production, as mentioned previously. The inhalation of PGE<sub>2</sub> has been shown to prevent the reaction to inhaled forms of acetylsalicylic acid (ie, lysine-aspirin), as well as the rise in cysLTs [<a href="#rid24">24</a>], suggesting that altered PGE<sub>2</sub> homeostasis may be key to this disorder. PGE<sub>2</sub> suppresses leukotriene production through the activity of protein kinase A (PKA), and PKA activity was shown to be abnormally low in granulocytes in the blood of patients with AERD, compared with controls [<a href="#rid51">51</a>]. Additionally, several isoforms of the PGE receptors are reduced on the inflammatory cells in nasal polyp and bronchial tissues of AERD patients, further suggesting that altered PGE homeostasis may contribute to AERD [<a href="#rid25">25,52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional evidence of a role for PGE<sub>2</sub> in AERD comes from laboratory studies. PGE<sub>2</sub>-synthase-1-deficient mice demonstrate sustained increases in airway resistance, mast cell activation, and cysLT overproduction following inhalation of lysine-aspirin, similar to AERD in humans [<a href="#rid53">53</a>]. These effects were blocked by pretreatment with leukotriene antagonists.</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Involvement of mast cells</span><span class="headingEndMark"> — </span>Mast cells, especially those in the nasal and bronchial epithelium, may represent an important source of lipid mediators in patients with AERD. Evidence for mast cell activation and degranulation during <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge in patients with AERD includes demonstrable elevations in mast cell tryptase, histamine, and PGD<sub>2</sub> [<a href="#rid35">35,46,54</a>]. In addition, H1 receptor antagonists (antihistamines) may reduce the extent of nasal and ocular reactions to aspirin to varying degrees.</p><p class="headingAnchor" id="H13"><span class="h2">Other areas of investigation</span><span class="headingEndMark"> — </span>Differences in complement proteins between asthmatics with and without <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> sensitivity were detected using proteomics [<a href="#rid55">55</a>]. A small case-control study examined changes in expression of plasma proteins in six aspirin-sensitive and six aspirin-tolerant asthmatics at baseline and after aspirin challenge, compared with control patients without asthma. Baseline differences were detected in complement proteins, apolipoproteins, and albumin complexed with myristic acid, with significant up- and downregulation of these proteins after aspirin challenge. In particular, patients with AERD had higher levels of C3a and C4a than tolerant patients at baseline, with levels that correlated to changes in forced expiratory volume in one second (FEV<sub>1</sub>) during challenge.</p><p class="headingAnchor" id="H347427262"><span class="h1">SIGNS AND SYMPTOMS</span><span class="headingEndMark"> — </span>Patients with AERD typically have asthma and chronic rhinosinusitis with nasal polyposis and experience acute exacerbations of upper and lower respiratory symptoms after the ingestion of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or other nonsteroidal anti-inflammatory drugs (NSAIDs) [<a href="#rid56">56</a>]. In most patients, the three component disorders develop sequentially over a period of years.</p><p class="headingAnchor" id="H1487508146"><span class="h2">Asthma</span><span class="headingEndMark"> — </span>Asthma usually develops in adulthood in patients who ultimately prove to have AERD [<a href="#rid7">7</a>]. Patients with AERD are more likely to have severe asthma, to have been intubated, and to require systemic glucocorticoids to control their symptoms compared with patients with aspirin-tolerant asthma [<a href="#rid57">57</a>]. However, a small percentage of those with AERD (estimated about less than 5 percent) have very mild asthma or are not aware that they have asthma. The inflammation in the lungs of patients with AERD is nearly always eosinophilic and more driven by cysteinyl leukotrienes compared with that in patients with aspirin-tolerant asthma [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H3109681765"><span class="h2">Chronic rhinosinusitis with nasal polyposis</span><span class="headingEndMark"> — </span>The majority of patients initially develop refractory rhinitis, which is usually established by their early 30s. This is followed by the development of chronic hypertrophic eosinophilic rhinosinusitis, characterized by nasal congestion, anosmia, and nasal polyposis  (<a class="graphic graphic_picture graphicRef73419" href="/z/d/graphic/73419.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef50105" href="/z/d/graphic/50105.html" rel="external">picture 2</a>). On computed tomography (CT), mucosal thickening typically affects most, if not all, of the paranasal sinuses, and polyps may appear as rounded mucosal protrusions in the nasal or sinus cavities. Hearing loss and eustachian tube dysfunction are also common [<a href="#rid60">60</a>]. Some patients have repeated sinus surgeries and polypectomies before the disorder is recognized. Sinus disease is a significant burden for many patients. In a survey of 190 patients, the majority reported that AERD adversely affected their quality of life and identified chronic nasal symptoms and decreased sense of smell as important factors [<a href="#rid61">61</a>]. Hyposmia and anosmia are even more common and severe in patients with AERD compared with aspirin-tolerant patients with CRS with nasal polyps [<a href="#rid62">62,63</a>]. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3729480564"><span class="h2">Acute reactions to NSAIDs</span><span class="headingEndMark"> — </span>Acute reactions to NSAIDs in patients with AERD typically begin 30 minutes to 3 hours after NSAID ingestion, peak at one to two hours after onset, and generally resolve by three hours from onset [<a href="#rid64">64,65</a>]. The symptoms are dose related (ie, small doses of NSAIDs may produce minimal symptoms, such as isolated nasal congestion), whereas larger doses may induce severe bronchospasm requiring intubation. Rare fatal reactions have been reported following full NSAID doses [<a href="#rid2">2</a>].</p><p>When patients with AERD are challenged with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> on an escalating dose schedule, most bronchoconstrictive reactions occur with low doses of 30 to 120 mg, although a few patients require 325 mg or more to elicit a reaction [<a href="#rid64">64</a>]. Thus, when an unknowing patient with AERD ingests 650 mg of aspirin or its equivalent of <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> (400 mg), <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a> (440 mg), or <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> (50 mg), reactions may be quite severe.</p><p>The classic reaction following NSAID ingestion consists of one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Nasal and ocular symptoms, including nasal congestion/obstruction, watery rhinorrhea, periorbital edema, and/or injection of the conjunctiva – These symptoms are often the first manifestation of the reaction. However, patients may not recognize the association if the NSAID is taken at the time of an upper respiratory infection or at a time when their baseline sinus disease symptoms are severe and uncontrolled.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asthmatic symptoms, including wheezing, dyspnea, cough, and chest tightness – These symptoms can be accompanied by a marked fall in forced expiratory volume in one second (FEV<sub>1</sub>). Bronchoconstriction is typically reversible with an inhaled beta-agonist bronchodilator, or it slowly reverses without treatment within several hours.</p><p></p><p>Additional symptoms may occur in patients with severe respiratory reactions. These include facial flushing/erythema, laryngospasm, abdominal cramps, epigastric pain, and hypotension. Severe reactions may be difficult or impossible to distinguish from immunoglobulin (Ig)E-mediated anaphylaxis.</p><p>A pruritic urticarial-like macular rash occurs in approximately 15 percent of AERD patients during these acute reactions  (<a class="graphic graphic_picture graphicRef126137 graphicRef126138" href="/z/d/graphic/126137.html" rel="external">picture 3A-B</a>). However, true urticaria and angioedema (without respiratory symptoms) are more characteristic of other distinct types of NSAID sensitivity without asthma, called NSAID-induced urticaria/angioedema (type 2 and 3 pseudoallergic reactions)  (<a class="graphic graphic_table graphicRef90304" href="/z/d/graphic/90304.html" rel="external">table 2</a>). Of note, macular rashes have been noted during these reactions as well [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions", section on 'Pseudoallergic reactions'</a>.)</p><p class="headingAnchor" id="H3658483570"><span class="h2">Other clinical manifestations</span><span class="headingEndMark"> — </span>Other clinical manifestations seen in some patients with AERD include reactions to alcoholic beverages, nonexertional chest pain, and otologic complications.</p><p class="headingAnchor" id="H87230559"><span class="h3">Reactions to alcoholic beverages</span><span class="headingEndMark"> — </span>Patients with AERD often report that alcoholic beverages induce symptoms in the upper (nasal congestion and rhinorrhea) and lower (wheezing, shortness of breath) respiratory tract [<a href="#rid61">61</a>]. In a questionnaire study of 59 patients with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge-confirmed AERD, 83 percent reported respiratory reactions to a variety of alcoholic drinks, with symptoms usually developing within an hour of ingestion [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H2607768532"><span class="h3">Chest pain</span><span class="headingEndMark"> — </span>Patients with AERD may report a nonexertional angina-like chest pain. In a retrospective review of 153 individuals with AERD, 10 reported episodes of chest pain, which was associated in several cases with a peripheral blood eosinophilia [<a href="#rid67">67</a>]. The pain was retrosternal, heavy, or squeezing in nature and radiated into the jaw, neck, or arms, with accompanying diaphoresis, nausea, or lightheadedness. It did not improve acutely with nitrates or longer-term with antihypertensives or statins. Of the 10 patients, 8 had initiated high-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy after undergoing an aspirin desensitization, and 6 of those patients reported that the chest pain began or worsened while they were on high-dose aspirin. Patients who underwent cardiac catheterization either had normal coronary arteries (without significant atherosclerosis) or showed evidence of coronary vasospasm. A course of glucocorticoids resulted in improvement or resolution in several patients. Until more is known about this entity, clinicians should be aware that patients with AERD may have angina-like chest pain in association with peripheral blood eosinophilia if no other cause can be identified. It has been speculated that the vasospasm may be related to eosinophils as indicated by the case report of resolution with steroid therapy, although further study is needed. The evaluation of coronary vasospasm is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1481.html" rel="external">"Vasospastic angina"</a>.)</p><p class="headingAnchor" id="H2877572611"><span class="h3">Otologic complications</span><span class="headingEndMark"> — </span>Some patients also report hearing loss as well as middle ear symptoms, including effusions, chronic ear drainage, otitis media requiring antibiotics as an adult, and, rarely, possible aural polyps [<a href="#rid68">68</a>]. In a survey of 660 patients with AERD, 28 percent reported a physician-diagnosed hearing loss that was unexplained by other identifiable causes [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H1162117833"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Variable laboratory findings include a peripheral eosinophilia and elevated levels of IgE.</p><p>Peripheral blood eosinophilia is common in AERD patients and correlates with severity of sinus disease in most studies [<a href="#rid69">69-72</a>]. In a series of 81 AERD patients, 51 percent had absolute eosinophil counts (AECs) &gt;450 cells/microliter [<a href="#rid69">69</a>]. In another cohort, absolute eosinophil counts (AECs) were between 1000 and 1500 in 10 percent of patients, and &gt;1500 in three percent [<a href="#rid73">73</a>]. However, an AEC &gt;1500 should prompt an evaluation for other causes of hypereosinophilia, the extent of which can be determined by the patient's clinical status.</p><p>Total serum IgE levels in patients with AERD are variable and do not tend to correlate with the severity of sinus disease [<a href="#rid70">70</a>]. The prevalence of atopic diseases, such as allergic rhinitis, is not clearly higher in patients with AERD [<a href="#rid74">74,75</a>]. However, some patients are sensitized to inhalant allergens, particularly perennial allergens such as dust mite [<a href="#rid76">76</a>]. Other patients have elevated total serum IgE in the absence of any discernable allergic disorders [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of AERD can often be made clinically when all three of the conditions that characterize AERD are present: asthma, visible nasal polyposis (or a history of nasal polypectomy), and a history of typical upper and lower respiratory symptoms after exposure to a nonsteroidal anti-inflammatory drug (NSAID). (See <a class="local">'Signs and symptoms'</a> above.) </p><p>A clinical diagnosis may be more difficult in patients with isolated asthma or isolated chronic rhinosinusitis (CRS) with nasal polyposis. In this case, a careful clinical history of symptoms following NSAID ingestion is required, possibly followed by diagnostic <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge, as discussed in the following sections.</p><p>The differentiation of pseudoallergic reactions, such as AERD, from allergic reactions to an individual NSAID is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Clinical diagnosis of NSAID intolerance</span><span class="headingEndMark"> — </span>When trying to determine whether a patient with asthma and/or nasal polyposis has had an adverse reaction to NSAIDs, it is helpful first to describe the symptoms of pseudoallergic reactions, as patients may not have previously recognized the association. NSAID sensitivity is an acquired condition, and the symptoms following NSAID ingestion are similar to flares in the underlying asthma and rhinosinusitis, so patients who were accustomed to taking these medications without difficulty often do not recognize the connection for some time. Clarifying the association with NSAID ingestion can be complicated, as the reason for NSAID ingestion, such as a respiratory infection or menstruation, may itself be a potential asthma trigger.</p><p>The absence of a history of an NSAID reaction does not exclude NSAID sensitivity. Studies in which NSAID intolerance was diagnosed by challenge have reported higher rates among the general asthmatic population compared with those that rely on history alone [<a href="#rid10">10</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Some patients have empirically avoided <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and NSAIDs for many years at the advice of providers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A small number of patients with NSAID intolerance may not recognize it because they are taking low daily doses of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> without obvious symptoms. This was observed in 7 patients in a series of 163 patients with AERD at one referral center [<a href="#rid78">78</a>]. Patients were taking 81 mg of aspirin daily. After stopping aspirin for at least 10 days, these patients had typical reactions to aspirin upon challenge, although with smaller decreases in forced expiratory volume in one second (FEV<sub>1</sub>) compared with other AERD patients. Four were subsequently desensitized to aspirin and responded to higher-dose therapy with improvements in nasal and asthma symptoms. Thus, the ability to tolerate low-dose aspirin therapy does not exclude the possibility of NSAID intolerance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are receiving <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> [<a href="#rid79">79-81</a>] or <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> [<a href="#rid82">82</a>] may either not react at all to NSAIDs or have such reduced reactions that they are not noticeable.</p><p></p><p>If the clinical history suggests a reaction to an NSAID, the clinician should then attempt to determine if the patient has reacted to more than one cyclooxygenase 1 (COX-1)-inhibiting NSAID, to exclude the possibility of an immunoglobulin (Ig)E-mediated reaction to a single NSAID. The patient should be questioned about any NSAID use SUBSEQUENT TO the first recognized reaction. NSAID ingestions BEFORE the first reaction are not relevant, since NSAID sensitivity is acquired, as reviewed previously. However, there is no evidence that previous NSAID use is required in order to develop NSAID sensitivity.</p><p>Among patients with asthma and significant rhinosinusitis after a careful history, there is an 80 percent likelihood of having a positive oral <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge with a history of a single NSAID reaction [<a href="#rid83">83</a>]. This increases to 90 percent with a history of reactions to two different NSAIDs.</p><p>Cutaneous symptoms to NSAIDs usually signify a different type of NSAID reaction (eg, NSAID-induced urticaria/angioedema). However, occasional patients with AERD have blended reactions (mixed respiratory and cutaneous). Thus, the presence of urticaria/angioedema does not exclude the possibility of AERD. (See  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions", section on 'Type 4: Blended reactions in otherwise asymptomatic individuals'</a>.)</p><p>While the majority of NSAIDs are administered orally, reactions can occur with <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a> given via intravenous or intramuscular injection or ophthalmic application.</p><p class="headingAnchor" id="H16"><span class="h2">Diagnostic aspirin challenge</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> challenge is the only way to definitively diagnose type 1 pseudoallergy to NSAIDs and thus AERD. Definitive diagnosis is important for research protocols involving AERD patients. Outside of research protocols, we typically reserve aspirin challenge for use as the first step in aspirin desensitization for patients with a specific need for regular NSAID therapy (ie, NSAIDs for rheumatologic disease, aspirin for cardiovascular disease, or aspirin for treatment of AERD).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of challenge</strong> – <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> challenges are generally performed orally in the United States. In other areas (eg, Europe), a liquid lysyl-acetylsalicylic acid derivative is available for intranasal or bronchial challenge. Intranasal <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a> is used in some research centers. However, inhaled challenges are purely diagnostic and not adequate for desensitization unless followed by oral aspirin. Protocols for aspirin challenge in patients with AERD are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization", section on 'Challenge protocols and procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premedication</strong> – In preparation for oral <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge or desensitization, patients with suspected AERD are usually pretreated with leukotriene-modifying agents (LTMAs), as these medications have been shown to dramatically reduce the severity of pulmonary reactions during the procedure. Despite the reduction in pulmonary symptoms, nasal and ocular symptoms still occur in most patients, such that the outcome of challenge should be apparent to the experienced clinician. Antihistamines are withheld for a week prior to the procedure, as they tend to blunt the nasal symptoms. (See  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization", section on 'Premedication for oral protocols'</a>.)</p><p></p><p class="bulletIndent1">Nasal or inhaled glucocorticoids (eg, intranasal, inhaled, or in combination with a long-acting beta-agonist) that are part of the patient's usual regimen should be continued up to and during the procedure. These medications decrease the likelihood of a serious episode of bronchoconstriction, but enough of the manifestations are not suppressed to enable a diagnosis of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> sensitivity. (See  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization", section on 'Provocation of symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staffing and location of challenge</strong> – <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> challenges are usually performed by allergy or pulmonary specialists with the expertise to manage any resultant symptoms and in settings equipped with the necessary medications, equipment, and support staff to manage acute bronchoconstriction or anaphylaxis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Challenge procedure</strong> – Oral <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge procedures vary among institutions but generally start with a low dose of aspirin, such as 30 to 41.5 mg, and advance by doubling doses approximately every 90 minutes to 3 hours [<a href="#rid65">65</a>]. The details of aspirin challenge are provided separately. (See  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization", section on 'Oral aspirin challenge'</a>.)</p><p></p><p class="headingAnchor" id="H692958125"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of each of the components of AERD is reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14609.html" rel="external">"Nasal obstruction: Diagnosis and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions"</a>.)</p><p></p><p class="headingAnchor" id="H302820590"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H4191924707"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The main goals of therapy are to control asthma and chronic rhinosinusitis (CRS) symptoms and to prevent the regrowth of nasal polyps. Most patients will require lifelong therapy, so it is important to use shared decision making to create a long-term plan that the patient understands and supports. The approach to different patient groups is described here and is consistent with, but not identical to, guidelines for CRS with nasal polyposis and advice on AERD from expert panels [<a href="#rid84">84-86</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p>The important components of therapy for AERD are:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of the patient's asthma, including a trial of leukotriene-modifying agents. (See <a class="local">'Asthma therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical and surgical management of CRS with nasal polyposis. (See <a class="local">'Management of sinus disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of cyclooxygenase 1 (COX-1)-inhibiting NSAIDs, unless the patient is a candidate for <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> desensitization followed by daily nonsteroidal anti-inflammatory drug (NSAID) therapy. (See <a class="local">'NSAID avoidance'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible use of biologic therapies, such as <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>, <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>, or <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, for treatment of both asthma and sinus disease. (See <a class="local">'Biologic agents'</a> below.)</p><p></p><p class="headingAnchor" id="H1135060734"><span class="h2">NSAID avoidance</span><span class="headingEndMark"> — </span>Patients with AERD should avoid all NSAIDs that inhibit COX-1  (<a class="graphic graphic_table graphicRef62880" href="/z/d/graphic/62880.html" rel="external">table 1</a>), unless they have been desensitized to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. The following alternatives are usually tolerated and can be given for the treatment of pain and/or inflammation, although exquisitely sensitive patients may react to higher doses of nonacetylated salicylates or <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>NSAIDs with very weak COX-1 inhibitory properties (eg, nonacetylated salicylates, such as <a class="drug drug_general" data-topicid="9876" href="/z/d/drug information/9876.html" rel="external">salsalate</a> and others)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a> (at doses up to 650 mg; as many as 20 percent of AERD patients will react to a dose of 1000 mg) [<a href="#rid87">87</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Highly selective COX-2 inhibitors (eg, <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a>) [<a href="#rid88">88</a>]</p><p></p><p>The optimal use of these alternative agents in patients with AERD is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions", section on 'Types 1 to 4: Treatment options'</a>.)</p><p>Note that patients who have been desensitized to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and are on daily aspirin therapy can take other NSAIDs normally. (See <a class="local">'Aspirin desensitization and daily therapy'</a> below.)</p><p class="headingAnchor" id="H2632429416"><span class="h2">Initial therapies</span><span class="headingEndMark"> — </span>For the majority of patients who present with all the manifestations of AERD, we attempt to optimize asthma management according to guideline-based care and administer a trial of antileukotriene drugs if not done previously (see <a class="local">'Leukotriene-modifying agents'</a> below). For nasal polyps, if not already tried, we initiate daily nasal washes with <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> solution (eg, respules intended for use in nebulizers) mixed with normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>. Sometimes these interventions are enough to control symptoms adequately.</p><p class="headingAnchor" id="H1712837143"><span class="h3">Asthma therapies</span><span class="headingEndMark"> — </span>Guideline-based asthma management utilizing a step-wise approach is the same for patients with and without AERD, except that patients with AERD sometimes experience more dramatic improvement in asthma symptoms with leukotriene-modifying agents, compared with those without AERD. Guidelines for asthma therapy are discussed in detail elsewhere  (<a class="graphic graphic_table graphicRef127798" href="/z/d/graphic/127798.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/532.html" rel="external">"Ongoing monitoring and titration of asthma therapies in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H399871043"><span class="h4">Leukotriene-modifying agents</span><span class="headingEndMark"> — </span>For patients with AERD and moderate-to-severe asthma, we recommend adding a leukotriene-modifying agent (LTMA) to their other asthma therapy if symptoms are not fully controlled. To varying degrees, these medications address the underlying dysregulation of leukotriene production in AERD and also protect patients from severe exacerbations due to accidental NSAID exposure [<a href="#rid43">43-45,89-91</a>]. (See  <a class="medical medical_review" href="/z/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma"</a>.)</p><p>Leukotriene modifying agents (LTMAs) provide significant benefit to a subset of patients. Specific agents include  (<a class="graphic graphic_table graphicRef77367" href="/z/d/graphic/77367.html" rel="external">table 4</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Leukotriene-receptor antagonists (LTRAs; eg, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>, pranlukast [available in Japan and some other countries, not in the United States]), which inhibit the actions of leukotrienes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">Zileuton</a>, which inhibits 5-lipoxygenase (5-LO) and blocks the synthesis of leukotrienes. Zileuton can be especially helpful for blunting reactions to NSAIDs and alcoholic beverages.</p><p></p><p>For patients who have not been treated with LTMAs in the past, we usually begin with an LTRA (eg, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>) because they are straightforward to administer. If there is no clinical improvement after four to six weeks, we add or substitute <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a>. Zileuton works quickly and if there is no improvement within a week or two, it can also be stopped. For patients who improve on a LTMA, we continue that agent long term. In our experience, zileuton is more effective, and, in a survey of patients with AERD, respondents identified zileuton as "extremely effective" more often than LTRAs [<a href="#rid61">61</a>]. However, zileuton requires twice-daily administration, periodic monitoring of liver function tests, and has some potential drug interactions.</p><p>While the simultaneous use of <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> and a LTRA has not been formally studied, it has been described in case series and reviews [<a href="#rid92">92-94</a>]. Combination therapy may be advantageous in patients who do not achieve disease control with either of the individual agents. The rationale for combination therapy is based upon studies demonstrating that patients with AERD have elevated cysteinyl leukotriene (cysLT) levels and receptor numbers, as well as upregulation of 5-LO. Thus, combination therapy may address these abnormalities more completely.</p><p class="headingAnchor" id="H2680144254"><span class="h3">Management of sinus disease</span><span class="headingEndMark"> — </span>Medical management for all patients begins with intranasal corticosteroids in the form of nasal sprays or irrigations, if these have not already been tried. However, patients with extensive polyposis may not be able to use these therapies because their nasal passages are completely obstructed. The medical and surgical management of CRS with nasal polyposis are presented separately. (See  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H630750058"><span class="h2">Advanced therapies: Our approach</span><span class="headingEndMark"> — </span>If the interventions above do not control symptoms or have already been tried without success in the past, we then either pursue <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> desensitization followed by daily aspirin therapy or we begin a biologic (usually <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>).</p><p class="headingAnchor" id="H4223378130"><span class="h3">Choosing between biologics and aspirin</span><span class="headingEndMark"> — </span>We consider multiple factors, as well as patient preferences, when choosing between these two therapies.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> desensitization and daily aspirin therapy improves asthma and CRS symptoms in 80 to 90 percent of patients [<a href="#rid95">95,96</a>] (see <a class="local">'Aspirin desensitization and daily therapy'</a> below). We prefer aspirin therapy for the following types of patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Those who prefer the idea of using an inexpensive, readily-available medication that has well-known side effects and benefits. It is also important that patients choosing <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> are amenable to undergoing sinus surgery to remove existing polyps, because clinical experience suggests that aspirin effectively slows the regrowth of polyps but only minimally shrinks existing polyps. For this reason, we recommend sinus surgery prior to aspirin desensitization and daily aspirin therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who are interested in taking <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or another NSAID either daily or intermittently for other reasons (eg, pain, rheumatologic diseases, or cardiac disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We prefer <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> for the following types of patients (see <a class="local">'Biologic agents'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Those who wish to avoid sinus surgery, because <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> does shrink existing polyps to varying degrees.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Those for whom severe asthma is the most significant problem, despite Global Initiative for Asthma (GINA) step 4 to 5 therapy  (<a class="graphic graphic_table graphicRef127798" href="/z/d/graphic/127798.html" rel="external">table 3</a>), since <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge and desensitization can induce significant pulmonary symptoms in patients with low baseline lung function, and a prebronchodilator forced expiratory volume in one second (FEV<sub>1</sub>) of ≤70 percent of the patient's best or ≤1.5 L is usually considered a contraindication to aspirin challenge. (See  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization", section on 'Contraindications to challenge'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a history of gastric ulcers or gastrointestinal bleeding, as daily <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is likely to aggravate these problems. Similarly, patients whose occupations involve risk of trauma, in whom bleeding would be potentially serious problem, or older adult patients in whom bleeding risk is higher.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Those who have already tried daily <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy and experienced regrowth of nasal polyps despite it.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who are younger than 18 years of age, because <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> use is discouraged in children due to the risk of Reye syndrome, and polyposis at this age should raise a concern of possible cystic fibrosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who do not have access to a clinician or center that can perform <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> desensitization.</p><p></p><p class="headingAnchor" id="H1102150947"><span class="h4">Relative efficacy</span><span class="headingEndMark"> — </span>Studies directly comparing biologic agents to each other and to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> desensitization and daily aspirin therapy for CRS with nasal polyposis are lacking. A network meta-analysis (NMA) indirectly compared the findings of 29 randomized trials for six patient-important outcomes: health-related quality of life, symptoms, smell, need for rescue oral glucocorticoids, and need for rescue polyp surgery [<a href="#rid97">97</a>]. <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a> showed the most benefit overall. Aspirin reduced symptoms but was associated with the highest rate of adverse effects. However, there were several important limitations to this NMA. In the studies evaluating the effects of aspirin therapy, all patients had AERD, which is generally more difficult to treat, whereas in the studies of biologics, the number of patients with AERD was highly variable and sometimes not reported. In addition, aspirin is most helpful when it is started immediately after sinus surgery, as soon as the patient has been cleared by the otolaryngologist, as it appears to prevent regrowth of polyps more consistently than shrinking existing polyps, and not all the studies of aspirin involved patients who had preceding surgery. Finally, at least one of the five studies of aspirin used a low dose that has not been proven effective. Thus, this meta-analysis was helpful in comparing biologics to each other but did not clarify the efficacy of aspirin therapy relative to the biologics for patients with AERD specifically.</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Aspirin desensitization and daily therapy</span><span class="headingEndMark"> — </span>Nearly all AERD patients can be successfully desensitized to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. Uncommon exceptions include patients with <strong>type 4</strong> or blended reactions with a history of urticaria occurring as part of a respiratory reaction to NSAIDs (particularly more than one NSAID). Patients with type 4 reactions are less likely to experience successful desensitization. Another small subset of patients will not be able to complete the aspirin desensitization procedure because of refractory nausea, abdominal pain, and diarrhea, and these patients often also develop other extra-pulmonary symptoms during their reactions, specifically the appearance of an erythematous, pruritic, macular dermatitis  (<a class="graphic graphic_picture graphicRef126137" href="/z/d/graphic/126137.html" rel="external">picture 3A</a> and <a class="graphic graphic_picture graphicRef126138" href="/z/d/graphic/126138.html" rel="external">picture 3B</a>) [<a href="#rid17">17,23</a>]. Urticaria that persists can also be a reason for failure  (<a class="graphic graphic_picture graphicRef78544" href="/z/d/graphic/78544.html" rel="external">picture 4</a>). Rarely, a patient may develop lower respiratory symptoms that do not resolve between doses, and we may abort the protocol if the patient's symptoms cannot be controlled within a few hours.</p><p>The protocol for desensitization is essentially a continuation of the challenge procedure, which is described in detail separately. (See <a class="local">'Diagnostic aspirin challenge'</a> above and  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization"</a>.)</p><p class="headingAnchor" id="H2322763076"><span class="h3">Prerequisite surgery</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> therapy is best initiated shortly after surgical polypectomy because aspirin prevents the regrowth of polyps but has minimal effect on existing polyps, and reactions to aspirin during desensitization are usually more severe if there is a heavy polyp burden present at the time.</p><p class="headingAnchor" id="H422774337"><span class="h3">Dosing and monitoring</span><span class="headingEndMark"> — </span>We aim to perform <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> desensitization within three months of surgical polypectomy. We begin daily therapy with high-dose aspirin (650 mg twice daily) and reassess in three months. At this dose, benefit was seen in 65 to 87 percent of 126 patients treated for 6 to 12 months in a prospective, uncontrolled study [<a href="#rid95">95</a>]. An analysis of 137 patients with AERD referred to the Scripps Clinic and treated with aspirin for at least one year found that approximately one-half could successfully decrease the dose from 650 mg twice daily to 325 mg twice daily without a relapse of symptoms [<a href="#rid98">98</a>]. However, the other one-half required the higher dose to maintain improvement long term. Because approximately equal percentages of patients tolerated each of these doses but one-half clearly benefit <strong>only</strong> from the higher dose, it is logical to begin therapy at the higher dose, though some centers prefer to being at 325 mg twice daily to assess for side effects and then increase to 650 mg twice daily if the patient is tolerating the aspirin well. Only occasional patients derived lasting benefit from 325 mg once daily, so this dose is considered too low for maintenance for most patients.</p><p>Some patients will notice improvement within a week, while others may report slow, steady progress over weeks to months. If the patient is tolerating high-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, we continue it for 6 to 12 months. After this initial period, if the patient is improving and/or if their nasal polyps have not recurred, we usually try lowering the dose to 325 mg twice daily, but if the patient subsequently notices any increase in asthma or nasal symptoms, we resume 650 mg twice daily. If their nasal polyps grow back within 12 to 24 months while on high-dose aspirin, we consider aspirin therapy to have failed and try <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> next. When effective, daily aspirin therapy is continued indefinitely or until the patient develops an adverse effect that requires discontinuation. The evidence in support of the recommended dosing of aspirin is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization", section on 'Optimal aspirin dose for AERD'</a>.)</p><p>Once patients are on daily <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy, they are generally also able to tolerate other NSAIDs (<a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, etc) and can take those medicines if needed for pain, fever, or inflammatory conditions. However, there is no evidence that taking another NSAID daily prevents the regrowth of polyps in the same way that aspirin can.</p><p class="headingAnchor" id="H347428569"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Daily <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy can reduce upper and lower airway symptoms in patients with AERD, slow progression of nasal polyps, reduce patients' need for intranasal and systemic glucocorticoids, and improve quality of life. It is the authors' clinical impression that improvements in sinus symptoms tend to be more dramatic than improvements in asthma symptoms in many patients. The benefits of aspirin therapy on AERD have been demonstrated in a small number of randomized trials and several uncontrolled studies [<a href="#rid95">95,96,98-108</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a small randomized crossover trial involving 25 patients with AERD, subjects were desensitized to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, then treated with daily aspirin or placebo for three months, and then crossed over to the other intervention [<a href="#rid101">101</a>]. Patients receiving aspirin had significant improvement in nasal symptoms and use of nasal medications. Approximately one-half experienced improvements in asthma symptoms, although these changes did not reach statistical significance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another small randomized trial, the impact of daily <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy (624 mg once daily for six months) was compared with placebo in 20 patients with AERD (with aspirin intolerance) and 14 patients with asthma and chronic rhinosinusitis with nasal polyposis but without aspirin intolerance [<a href="#rid107">107</a>]. Primary outcomes included nasal symptoms, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsinonasaltest.wustl.edu%2F&amp;token=ucDrxnLuYNidf73NHuLMBRTVpp4sxVxKfd7KHWEY5Ccf0So3OUW7xDw%2BNOGjp6mn&amp;TOPIC_ID=520" target="_blank">Sino-Nasal Outcomes Test (SNOT-20)</a> scores, peak nasal inspiratory flows, Asthma Control Test (ACT) scores, and spirometric parameters. Only patients with AERD who received aspirin therapy showed significant improvements in these measures. Maintenance dose of inhaled glucocorticoids also decreased in the AERD group receiving aspirin. These findings also support the clinical observation that patients without aspirin intolerance do not benefit from aspirin therapy. Of note, the dose of aspirin used in this trial was relatively low, as some centers use 650 mg twice daily or even higher doses. (See  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization", section on 'Optimal aspirin dose for AERD'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An uncontrolled study examined 65 patients with AERD already receiving optimal medical management who were desensitized to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and received daily treatment for one to six years (mean of three years) [<a href="#rid104">104</a>]. Doses ranged from 325 mg once daily to 650 mg three times daily, with a mean dose of about 1200 mg daily. Clinical outcomes before desensitization and after varying periods of aspirin treatment were compared. Those taking aspirin experienced significant reductions in the numbers of sinus infections per year (median reduction was from six episodes to two), hospitalizations for treatment of asthma per year, improvement in olfaction, and reduction in use of systemic glucocorticoids. The need for sinus surgery/polypectomy decreased from an average of one surgery every 3 years to one every 10 years. In contrast, emergency department visits for asthma and use of inhaled glucocorticoids were unchanged.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study followed 172 patients with AERD who were desensitized to and treated with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> at a referral center and then discharged back to their original providers and followed with interviews [<a href="#rid95">95</a>]. The mean daily dose of aspirin was 1138 mg daily. By the first six months of aspirin treatment, there were significant reductions in the number of sinus infections and need for oral glucocorticoids and improvements in both nasal/sinus and asthma symptoms. Of the 126 patients who completed one year or more of aspirin treatment, 87 percent experienced a good to excellent response. Mean <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> doses decreased at six months and one year.</p><p></p><p class="bulletIndent1">The remaining 13 percent of patients did not experience noticeable improvement [<a href="#rid95">95</a>]. Most of these patients had concomitant forms of chronic rhinosinusitis in addition to AERD. For example, some were sensitized to perennial allergens and were generally not being treated for concomitant allergic rhinitis. Others had severe gastroesophageal reflux disease, allergic fungal rhinosinusitis, or other coexisting conditions that would not be altered by <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. Fourteen percent of patients discontinued aspirin because of various known side effects (mostly gastrointestinal intolerance).</p><p></p><p class="headingAnchor" id="H123123097"><span class="h3">Mechanism</span><span class="headingEndMark"> — </span>The mechanism by which daily <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> therapy reduces asthma and sinus symptoms in patients with AERD remains unclear. An initial hypothesis was that chronic aspirin therapy somehow corrected the underlying perturbations observed in the disorder, but a prospective study of 42 patients with AERD showed that eight weeks of high-dose aspirin (650 mg twice daily) paradoxically increased markers of type 2 inflammation, an effect that was unique to these patients and not seen in subjects with aspirin-tolerant asthma [<a href="#rid109">109</a>]. Specifically, aspirin therapy increased the already constitutively high cysLT production and further reduced abnormally low prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) levels in the urine. A subsequent explanation for the ability of aspirin to improve symptoms while worsening the abnormalities often measured in AERD is the drug's ability to impair the production of PGD<sub>2</sub> by mast cells [<a href="#rid110">110</a>]. PGD<sub>2</sub> can be pro-inflammatory and drive recruitment and activation of various inflammatory cells [<a href="#rid111">111</a>]. Thus, these findings suggest that overproduction of PGD<sub>2</sub> may contribute to the pathobiology of AERD, although further study of this mediator and the receptors through which it acts is needed.</p><p class="headingAnchor" id="H730355464"><span class="h3">Avoiding gastrointestinal toxicity</span><span class="headingEndMark"> — </span>The development of gastric irritation from daily <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is reported by up to one-half of patients, although not all these patients have symptoms severe enough to cause them to stop therapy. The risk of gastrointestinal (GI) toxicity should be assessed and reviewed with the patient prior to choosing aspirin therapy and at follow-up visits. We generally avoid aspirin in patients with past peptic ulcer disease or severe gastritis. For patients with a history of mild gastritis that has resolved, we empirically coadminister a proton pump inhibitor (PPI). We prefer PPIs (eg, <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">lansoprazole</a> [15 or 30 mg daily] or <a class="drug drug_general" data-topicid="9104" href="/z/d/drug information/9104.html" rel="external">esomeprazole</a> [20 or 40 mg daily]) over H2 receptor antagonists or <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> because H2 antagonists are less effective than PPIs, and misoprostol is difficult to tolerate due to gastrointestinal side effects (see  <a class="medical medical_review" href="/z/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a>). We also advise desensitized patients to take their daily aspirin doses after a meal and to use enteric-coated tablets, although the impact of these precautions may be limited. Tolerance of daily aspirin in patients with AERD is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15539.html" rel="external">"Aspirin-exacerbated respiratory disease: NSAID challenge and desensitization", section on 'Reasons for discontinuation'</a>.)</p><p class="headingAnchor" id="H852337044"><span class="h2">Biologic agents</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a>, <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>, and <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> have been available for the treatment of moderate-to-severe asthma  (<a class="graphic graphic_table graphicRef118483" href="/z/d/graphic/118483.html" rel="external">table 5</a>). In the United States, these three agents are also approved by the US Food and Drug Administration (FDA) for treatment of CRS with nasal polyposis. Based on a network meta-analysis indirectly comparing these three biologics, dupilumab showed the most benefit overall [<a href="#rid97">97</a>].</p><p>While <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> desensitization can be particularly effective for reducing nasal symptoms in AERD and is significantly less expensive, the use of biologics is evolving to take on a more prominent role, especially in those with severe asthma. In addition, not all centers have the expertise or experience to perform aspirin desensitizations, and biologics may be more practical for this reason.</p><p>A 2020 European position paper on rhinosinusitis (not specifically addressing those with AERD) proposed criteria to identify appropriate candidates for biologic therapies. Among patients with bilateral nasal polyposis who had previously undergone sinus surgery or who were not surgical candidates, the position paper suggested that three of the following five criteria should be met [<a href="#rid84">84</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of type 2 disease (tissue eosinophils ≥10 per high power field or blood eosinophils ≥250/microliter or total IgE ≥100 IU/mL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The need for at least two courses of systemic corticosteroids per year or &gt;3 months of low-dose systemic corticosteroids or who had a contraindication to systemic corticosteroids</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significantly impaired quality of life, as defined by a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsinonasaltest.wustl.edu%2F&amp;token=ucDrxnLuYNidf73NHuLMBRTVpp4sxVxKfd7KHWEY5Ccf0So3OUW7xDw%2BNOGjp6mn&amp;TOPIC_ID=520" target="_blank">SNOT-22</a> score ≥40</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anosmia on a smell test</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid asthma needing regular inhaled corticosteroids</p><p></p><p>Also relevant are the GINA guidelines for asthma, which suggest that patients with GINA steps 4 to 5 asthma, with peripheral eosinophils &gt;150/microliter (others contend &gt;300) and two steroid-requiring exacerbations in the past year, are appropriate for therapy with a biologic agent  (<a class="graphic graphic_table graphicRef127798" href="/z/d/graphic/127798.html" rel="external">table 3</a>). The choice between sinus surgery followed by <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> desensitization versus initiating a biologic should be made with the patient through shared decision-making.</p><p class="headingAnchor" id="H2058197036"><span class="h3">Dupilumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a> is a monoclonal antibody that blocks the shared interleukin (IL-) 4/IL-13 receptor. The approved dose of dupilumab for CRS with nasal polyposis is 300 mg given subcutaneously every other week (without a loading dose). If the primary indication is severe asthma, we give a 600 mg loading dose followed by 300 mg every 2 weeks. Patients should have an absolute eosinophil count ≥150/mcL unless they are receiving chronic oral corticosteroids.</p><p>In two multicenter randomized trials including 724 patients with CRS with nasal polyposis, 204 of whom had AERD, <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> therapy for 24 or 52 weeks resulted in significant improvements in the primary endpoints of nasal polyp scores, nasal congestion/obstruction, and sinus Lund-MacKay CT scores compared with placebo and was well tolerated [<a href="#rid112">112</a>]. Dupilumab-treated patients also experienced greater improvements in olfaction and in overall CRS symptoms as measured by <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsinonasaltest.wustl.edu%2F&amp;token=ucDrxnLuYNidf73NHuLMBRTVpp4sxVxKfd7KHWEY5Ccf0So3OUW7xDw%2BNOGjp6mn&amp;TOPIC_ID=520" target="_blank">SNOT-22</a>. Patients with AERD or asthma experienced improvements in lung function as well, a finding that was also noted in AERD patients in previous smaller studies [<a href="#rid113">113</a>]. A post-hoc analysis evaluated the safety and efficacy of dupilumab in the 28 percent of patients with AERD and CRS with nasal polyposis and found significantly greater benefit compared to similar patients without AERD [<a href="#rid114">114</a>]. Dupilumab is generally well tolerated by patients with AERD, although several conditions, including seronegative arthritis, enthesitis/enthesopathy, psoriasis, and iridocyclitis have been linked to its use [<a href="#rid115">115,116</a>]. Longer term safety will require time to assess.</p><p class="headingAnchor" id="H22089120"><span class="h3">Omalizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">Omalizumab</a> is approved by the FDA for inadequately controlled moderate-to-severe asthma and for CRS with nasal polyposis. In our allergy clinic, we have used omalizumab in a small number of patients with severe AERD with mixed results. Most of these individuals either could not take <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or did not improve sufficiently with aspirin therapy.</p><p>A small trial suggested that <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> (an anti-IgE monoclonal antibody) may be helpful in patients with nasal polyps [<a href="#rid117">117</a>]. In 24 patients with CRS with nasal polyposis and concomitant asthma, approximately one-half of whom had AERD, subjects received four to eight subcutaneous doses of omalizumab or placebo, consistent with omalizumab dosing guidelines for asthma (based on serum IgE level and body mass) [<a href="#rid117">117</a>]. Omalizumab treatment was associated with improved airway symptoms and quality of life and with a significant decrease in total endoscopic nasal polyposis scores after 16 weeks compared with placebo. Changes in polyposis scores were confirmed by means of sinus CT scoring (Lund-MacKay score) and were independent of the presence of allergy. However, in the subset of patients with AERD, sinus CT did not show clear improvement. Thus, it is unclear whether this agent is as beneficial for patients with AERD.</p><p>In several case reports of patients with AERD and severe asthma, <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> was associated with clinical improvement in asthma and loss of sensitivity to oral <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge [<a href="#rid81">81,118,119</a>]. The dosing and administration of omalizumab for asthma are described separately. (See  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Administration'</a>.)</p><p class="headingAnchor" id="H852337057"><span class="h3">Mepolizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">Mepolizumab</a> is an anti-IL-5 monoclonal antibody that is beneficial in patients with severe asthma and blood or sputum eosinophilia and also those with CRS and nasal polyposis, as reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Anti-IL-5 therapy'</a> and  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Anti-IL-5 (mepolizumab)'</a>.)</p><p>In a randomized, phase 3, multinational SYNAPSE trial of over 400 adults with recurrent, severe bilateral nasal polyps and at least one polyp surgery in the past 10 years, patients received either 100 mg <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> subcutaneously or placebo every 4 weeks for 52 weeks [<a href="#rid120">120</a>]. All patients also received standard care: <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> nasal irrigations, <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a> furoate intranasal spray for at least 8 weeks, and systemic corticosteroids or antibiotics or both as required. Mepolizumab therapy improved nasal polyp size (adjusted difference in median endoscopic nasal polyp score -0.73, 95% CI -1.11 to -0.34) and nasal obstruction scores (-3.14, 95% CI -4.09 to -2.18) compared with placebo and was well-tolerated. However, olfaction did not improve.</p><p class="headingAnchor" id="H2978248998"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>AERD is a persistent condition that does not resolve spontaneously. Once a patient has found an effective therapy that they tolerate, treatment is continued indefinitely.</p><p class="headingAnchor" id="H517580603"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110441.html" rel="external">"Society guideline links: Chronic rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Aspirin-exacerbated respiratory disease (AERD; also called nonsteroidal anti-inflammatory drug [NSAID]-exacerbated respiratory disease, or NERD) describes patients with the triad of asthma, chronic rhinosinusitis (CRS) with nasal polyposis, and intolerance to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or other NSAIDs. Within 30 minutes to 3 hours after ingesting an NSAID, patients develop a sudden worsening of asthma and nasal congestion, sometimes accompanied by other symptoms. AERD affects 5 to 20 percent of all patients with asthma and typically presents in adulthood. (See <a class="local">'Signs and symptoms'</a> above and <a class="local">'Terminology'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – The pathophysiology of AERD involves acquired perturbations in arachidonic acid (AA) metabolism and a resulting imbalance between proinflammatory and anti-inflammatory mediators, leading to chronic upper and lower airway inflammation. The pharmacologic action of cyclooxygenase 1 (COX-1)-inhibiting NSAIDs acutely exacerbates this imbalance and also results in mast cell activation. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A working diagnosis of AERD is usually made clinically based upon the presence of the three characteristic component disorders (ie, asthma, CRS with nasal polyposis, and a history of NSAID reactions). Definitive diagnosis requires <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> challenge, although this degree of diagnostic precision is rarely needed outside of research protocols. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/2085.html" rel="external">"Diagnostic challenge and desensitization protocols for NSAID reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> – Patients with AERD should initially be managed according to guideline-based therapy for asthma and medical and surgical management of CRS with nasal polyposis. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Avoidance of NSAIDs</strong> – Patients with AERD should avoid all NSAIDs that inhibit COX-1  (<a class="graphic graphic_table graphicRef62880" href="/z/d/graphic/62880.html" rel="external">table 1</a>), unless they have been desensitized to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. (See <a class="local">'NSAID avoidance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intranasal corticosteroids </strong>– Nasal congestion and anosmia due to nasal polyposis are initially managed with corticosteroid nasal sprays or irrigations. Endoscopic sinus surgery is often required if nasal polyposis is extensive. The management of CRS with nasal polyposis is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leukotriene-modifying agents</strong> – For patients with AERD and moderate-to-severe asthma, we recommend adding a leukotriene-modifying agent (LTMA) to their other asthma therapy, if symptoms are not fully controlled (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We usually begin with a leukotriene-receptor antagonist (LTRA; eg, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>). If there is no clinical improvement after four to six weeks, we add or substitute the 5-lipoxygenase (5-LO) inhibitor <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a>. If there is no improvement in response to zileuton, it can also be stopped. (See <a class="local">'Leukotriene-modifying agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapy for persistent disease </strong>– For patients with AERD and chronic rhinosinusitis with nasal polyposis who have symptoms that persist despite LTMAs and intranasal corticosteroids, we recommend adding either an asthma biologic or performing <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> desensitization followed by daily aspirin therapy, rather than resorting to intermittent oral corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Of the available asthma biologics, we prefer <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>.</p><p></p><p class="bulletIndent1">The choice between <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> and <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> depends on several patient characteristics (see <a class="local">'Choosing between biologics and aspirin'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dupilumab</strong> – We prefer <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> for patients with severe or unstable asthma, patients who cannot tolerate <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or have potential contraindications, and/or patients who have failed aspirin therapy previously. The dose for CRS with nasal polyposis is 300 mg given subcutaneously every other week. Other biologics may also be effective but have not been as extensively studied. (See <a class="local">'Biologic agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aspirin</strong><strong> desensitization and daily therapy</strong> – We prefer <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> desensitization and daily aspirin therapy for patients who wish to take aspirin (or other NSAIDs) for other reasons (eg, rheumatologic disease, cardiovascular risk) and patients who prefer to take a drug that is inexpensive and well-studied. For patients with significant polyposis, aspirin therapy is best initiated shortly after polyp surgery, because aspirin slows the regrowth of polyps but has minimal effect on existing polyps. Therefore, patients choosing aspirin therapy should be amenable to polypectomy before undergoing desensitization. (See <a class="local">'Aspirin desensitization and daily therapy'</a> above.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> desensitization should be performed by clinicians (usually allergists or pulmonologists) with expertise in the technique and in a setting that is equipped to treat the range of reactions that may result. We suggest an initial aspirin dose of 650 mg orally twice daily rather than lower doses (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We evaluate the patient's response to therapy after three months. If symptoms have improved, the dose may be lowered to 325 mg twice daily. If symptoms have stabilized, we continue for a longer period and reassess. If symptoms have worsened, we stop aspirin and change to <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>. (See <a class="local">'Dosing and monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – AERD is a persistent disorder that requires lifelong management. Therapies that are effective and well-tolerated for an individual patient are continued indefinitely. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68:975.</a></li><li><a class="nounderline abstract_t">Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24:113.</a></li><li><a class="nounderline abstract_t">Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89:474.</a></li><li><a class="nounderline abstract_t">Bensko JC, McGill A, Palumbo M, et al. Pediatric-onset aspirin-exacerbated respiratory disease: Clinical characteristics, prevalence, and response to dupilumab. J Allergy Clin Immunol Pract 2022; 10:2466.</a></li><li><a class="nounderline abstract_t">Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16:432.</a></li><li><a class="nounderline abstract_t">Roland LT, Wang H, Mehta CC, et al. Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database. Int Forum Allergy Rhinol 2019; 9:1420.</a></li><li><a class="nounderline abstract_t">Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol 2015; 135:676.</a></li><li><a class="nounderline abstract_t">Stevens WW, Peters AT, Hirsch AG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2017; 5:1061.</a></li><li><a class="nounderline abstract_t">Nabavi M, Esmaeilzadeh H, Arshi S, et al. Aspirin hypersensitivity in patients with chronic rhinosinusitis and nasal polyposis: frequency and contributing factors. Am J Rhinol Allergy 2014; 28:239.</a></li><li><a class="nounderline abstract_t">Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328:434.</a></li><li><a class="nounderline abstract_t">Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999; 28:717.</a></li><li><a class="nounderline abstract_t">Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913.</a></li><li class="breakAll">Shore SA, Austen KF, Drazen JM. Lung biology in health and disease: Lung cell biology. In: Eicosanoids and the lung, L'Enfant C, Massaro D (Eds), Marcel Dekker, New York 1989.</li><li><a class="nounderline abstract_t">Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341:989.</a></li><li><a class="nounderline abstract_t">Dahlén B. Treatment of aspirin-intolerant asthma with antileukotrienes. Am J Respir Crit Care Med 2000; 161:S137.</a></li><li><a class="nounderline abstract_t">Narayanankutty A, Reséndiz-Hernández JM, Falfán-Valencia R, Teran LM. Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD). Clin Biochem 2013; 46:566.</a></li><li><a class="nounderline abstract_t">Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2015; 135:245.</a></li><li><a class="nounderline abstract_t">Sladek K, Dworski R, Soja J, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149:940.</a></li><li><a class="nounderline abstract_t">Antczak A, Montuschi P, Kharitonov S, et al. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166:301.</a></li><li><a class="nounderline abstract_t">Knapp HR, Sladek K, Fitzgerald GA. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med 1992; 119:48.</a></li><li><a class="nounderline abstract_t">Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988; 137:847.</a></li><li><a class="nounderline abstract_t">Daffern PJ, Muilenburg D, Hugli TE, Stevenson DD. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 1999; 104:559.</a></li><li><a class="nounderline abstract_t">Lee TH, Woszczek G, Farooque SP. Leukotriene E4: perspective on the forgotten mediator. J Allergy Clin Immunol 2009; 124:417.</a></li><li><a class="nounderline abstract_t">Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153:572.</a></li><li><a class="nounderline abstract_t">Ying S, Meng Q, Scadding G, et al. Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol 2006; 117:312.</a></li><li><a class="nounderline abstract_t">Babu KS, Salvi SS. Aspirin and asthma. Chest 2000; 118:1470.</a></li><li><a class="nounderline abstract_t">Mastalerz L, Sanak M, Gawlewicz-Mroczka A, et al. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 2008; 63:27.</a></li><li><a class="nounderline abstract_t">Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012; 119:3790.</a></li><li><a class="nounderline abstract_t">Maclouf JA, Murphy RC. Transcellular metabolism of neutrophil-derived leukotriene A4 by human platelets. A potential cellular source of leukotriene C4. J Biol Chem 1988; 263:174.</a></li><li><a class="nounderline abstract_t">Guilemany JM, Roca-Ferrer J, Mullol J. Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis. Curr Allergy Asthma Rep 2008; 8:219.</a></li><li><a class="nounderline abstract_t">Stevenson DD, Zuraw BL. Pathogenesis of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24:169.</a></li><li><a class="nounderline abstract_t">Cai Y, Bjermer L, Halstensen TS. Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma. Am J Respir Cell Mol Biol 2003; 29:683.</a></li><li><a class="nounderline abstract_t">Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101:834.</a></li><li><a class="nounderline abstract_t">Nasser S, Christie PE, Pfister R, et al. Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects. Thorax 1996; 51:64.</a></li><li><a class="nounderline abstract_t">Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94:1046.</a></li><li><a class="nounderline abstract_t">Adamjee J, Suh YJ, Park HS, et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol 2006; 209:392.</a></li><li><a class="nounderline abstract_t">Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350:1599.</a></li><li><a class="nounderline abstract_t">Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23:290.</a></li><li><a class="nounderline abstract_t">Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347:1493.</a></li><li><a class="nounderline abstract_t">Sanak M, Levy BD, Clish CB, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000; 16:44.</a></li><li><a class="nounderline abstract_t">Gaber F, Daham K, Higashi A, et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008; 63:1076.</a></li><li><a class="nounderline abstract_t">Jerschow E, Edin ML, Chi Y, et al. Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2019; 7:1580.</a></li><li><a class="nounderline abstract_t">Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148:1447.</a></li><li><a class="nounderline abstract_t">Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&amp;F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144:957.</a></li><li><a class="nounderline abstract_t">Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994; 49:749.</a></li><li><a class="nounderline abstract_t">Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003; 111:743.</a></li><li><a class="nounderline abstract_t">Campo P, Ayuso P, Salas M, et al. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. Allergy 2013; 68:1001.</a></li><li><a class="nounderline abstract_t">Picado C, Fernandez-Morata JC, Juan M, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999; 160:291.</a></li><li><a class="nounderline abstract_t">Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000; 161:391.</a></li><li><a class="nounderline abstract_t">Pierzchalska M, Szabó Z, Sanak M, et al. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J Allergy Clin Immunol 2003; 111:1041.</a></li><li><a class="nounderline abstract_t">Laidlaw TM, Cutler AJ, Kidder MS, et al. Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2014; 133:1692.</a></li><li><a class="nounderline abstract_t">Corrigan CJ, Napoli RL, Meng Q, et al. Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma. J Allergy Clin Immunol 2012; 129:1636.</a></li><li><a class="nounderline abstract_t">Liu T, Laidlaw TM, Katz HR, Boyce JA. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci U S A 2013; 110:16987.</a></li><li><a class="nounderline abstract_t">Cahill KN, Murphy K, Singer J, et al. Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2019; 143:799.</a></li><li><a class="nounderline abstract_t">Lee SH, Rhim T, Choi YS, et al. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med 2006; 173:370.</a></li><li><a class="nounderline abstract_t">Haque R, White AA, Jackson DJ, Hopkins C. Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2021; 148:283.</a></li><li><a class="nounderline abstract_t">Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970.</a></li><li><a class="nounderline abstract_t">Comhair SAA, Bochenek G, Baicker-McKee S, et al. The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease. Respir Res 2018; 19:210.</a></li><li><a class="nounderline abstract_t">Laidlaw TM, Fuentes DJ, Wang Y, et al. Efficacy of Zileuton in Patients with Asthma and History of Aspirin Sensitivity: A Retrospective Analysis of Data from Two Phase 3 Studies. J Allergy Clin Immunol 2017; 139:AB384.</a></li><li><a class="nounderline abstract_t">Mullur J, Singer J, Roditi R, Cahill KN. Hearing loss and middle ear symptoms in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2019; 7:1671.</a></li><li><a class="nounderline abstract_t">Ta V, White AA. Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2015; 3:711.</a></li><li><a class="nounderline abstract_t">Gudziol V, Michel M, Sonnefeld C, et al. Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. Eur Arch Otorhinolaryngol 2017; 274:1487.</a></li><li><a class="nounderline abstract_t">Morse JC, Shilts MH, Ely KA, et al. Patterns of olfactory dysfunction in chronic rhinosinusitis identified by hierarchical cluster analysis and machine learning algorithms. Int Forum Allergy Rhinol 2019; 9:255.</a></li><li><a class="nounderline abstract_t">Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2009; 123:406.</a></li><li><a class="nounderline abstract_t">DeGregorio GA, Singer J, Cahill KN, Laidlaw T. A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2019; 7:1174.</a></li><li><a class="nounderline abstract_t">Cardet JC, White AA, Barrett NA, et al. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract 2014; 2:208.</a></li><li><a class="nounderline abstract_t">Shah NH, Schneider TR, DeFaria Yeh D, et al. Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2016; 4:1215.</a></li><li><a class="nounderline abstract_t">Calvo-Henriquez C, Di Corso E, Alobid I, et al. Pathophysiological Link Between Chronic Rhinosinusitis and Ear Disease. Curr Allergy Asthma Rep 2023; 23:389.</a></li><li><a class="nounderline abstract_t">Fountain CR, Mudd PA, Ramakrishnan VR, et al. Characterization and treatment of patients with chronic rhinosinusitis and nasal polyps. Ann Allergy Asthma Immunol 2013; 111:337.</a></li><li><a class="nounderline abstract_t">Poznanovic SA, Kingdom TT. Total IgE levels and peripheral eosinophilia: correlation with mucosal disease based on computed tomographic imaging of the paranasal sinus. Arch Otolaryngol Head Neck Surg 2007; 133:701.</a></li><li><a class="nounderline abstract_t">Newman LJ, Platts-Mills TA, Phillips CD, et al. Chronic sinusitis. Relationship of computed tomographic findings to allergy, asthma, and eosinophilia. JAMA 1994; 271:363.</a></li><li><a class="nounderline abstract_t">Bryson JM, Tasca RA, Rowe-Jones JM. Local and systemic eosinophilia in patients undergoing endoscopic sinus surgery for chronic rhinosinusitis with and without polyposis. Clin Otolaryngol Allied Sci 2003; 28:55.</a></li><li class="breakAll">Dr. Tanya Laidlaw, personal communication.</li><li><a class="nounderline abstract_t">Shi J, Misso NL, Duffy DL, et al. Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy. Eur Respir J 2005; 26:249.</a></li><li><a class="nounderline abstract_t">Barranco P, Bobolea I, Larco JI, et al. Diagnosis of aspirin-induced asthma combining the bronchial and the oral challenge tests: a pilot study. J Investig Allergol Clin Immunol 2009; 19:446.</a></li><li><a class="nounderline abstract_t">Emanuel IA, Shah SB. Chronic rhinosinusitis: allergy and sinus computed tomography relationships. Otolaryngol Head Neck Surg 2000; 123:687.</a></li><li><a class="nounderline abstract_t">Johns CB, Laidlaw TM. Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy 2014; 28:287.</a></li><li><a class="nounderline abstract_t">Lee-Sarwar K, Johns C, Laidlaw TM, Cahill KN. Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2015; 3:449.</a></li><li><a class="nounderline abstract_t">Lang DM, Aronica MA, Maierson ES, et al. Omalizumab can inhibit respiratory reaction during aspirin desensitization. Ann Allergy Asthma Immunol 2018; 121:98.</a></li><li><a class="nounderline abstract_t">Phillips-Angles E, Barranco P, Lluch-Bernal M, et al. Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab. J Allergy Clin Immunol Pract 2017; 5:842.</a></li><li><a class="nounderline abstract_t">Aksu K, Kurt E. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease. Allergol Immunopathol (Madr) 2013; 41:208.</a></li><li><a class="nounderline abstract_t">Mustafa SS, Vadamalai K. Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2021; 126:738.</a></li><li><a class="nounderline abstract_t">Williams AN, Simon RA, Woessner KM, Stevenson DD. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol 2007; 120:273.</a></li><li><a class="nounderline abstract_t">Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58:1.</a></li><li><a class="nounderline abstract_t">Buchheit KM, Laidlaw TM, Levy JM. Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2021; 148:348.</a></li><li><a class="nounderline abstract_t">Stevens WW, Jerschow E, Baptist AP, et al. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2021; 147:827.</a></li><li><a class="nounderline abstract_t">Settipane RA, Schrank PJ, Simon RA, et al. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995; 96:480.</a></li><li><a class="nounderline abstract_t">Morales DR, Lipworth BJ, Guthrie B, et al. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. J Allergy Clin Immunol 2014; 134:40.</a></li><li><a class="nounderline abstract_t">Dahlén SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:9.</a></li><li><a class="nounderline abstract_t">Lee DK, Haggart K, Robb FM, Lipworth BJ. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J 2004; 24:226.</a></li><li><a class="nounderline abstract_t">Dahlén B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:1187.</a></li><li><a class="nounderline abstract_t">White A, Ludington E, Mehra P, et al. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol 2006; 97:688.</a></li><li><a class="nounderline abstract_t">Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 2011; 3:3.</a></li><li><a class="nounderline abstract_t">Lee RU, White AA, Ding D, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2010; 105:130.</a></li><li><a class="nounderline abstract_t">Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111:180.</a></li><li><a class="nounderline abstract_t">Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008; 63:1228.</a></li><li><a class="nounderline abstract_t">Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. J Allergy Clin Immunol 2022; 149:1286.</a></li><li><a class="nounderline abstract_t">Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007; 119:157.</a></li><li><a class="nounderline abstract_t">Esmaeilzadeh H, Nabavi M, Aryan Z, et al. Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial. Clin Immunol 2015; 160:349.</a></li><li><a class="nounderline abstract_t">Mortazavi N, Esmaeilzadeh H, Abbasinazari M, et al. Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease. Iran J Pharm Res 2017; 16:1639.</a></li><li><a class="nounderline abstract_t">Stevenson DD, Pleskow WW, Simon RA, et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984; 73:500.</a></li><li><a class="nounderline abstract_t">Sweet JM, Stevenson DD, Simon RA, Mathison DA. Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 1990; 85:59.</a></li><li><a class="nounderline abstract_t">Williams AN, Woessner KM. The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. Curr Allergy Asthma Rep 2008; 8:245.</a></li><li><a class="nounderline abstract_t">Stevenson DD, Hankammer MA, Mathison DA, et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996; 98:751.</a></li><li><a class="nounderline abstract_t">McMains KC, Kountakis SE. Medical and surgical considerations in patients with Samter's triad. Am J Rhinol 2006; 20:573.</a></li><li><a class="nounderline abstract_t">Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003; 90:338.</a></li><li><a class="nounderline abstract_t">Świerczyńska-Krępa M, Sanak M, Bochenek G, et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol 2014; 134:883.</a></li><li><a class="nounderline abstract_t">Cho KS, Soudry E, Psaltis AJ, et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg 2014; 151:575.</a></li><li><a class="nounderline abstract_t">Cahill KN, Cui J, Kothari P, et al. Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial. Am J Respir Crit Care Med 2019; 200:704.</a></li><li><a class="nounderline abstract_t">Borish L. Aspirin-exacerbated Respiratory Disease: A Syndrome of Mast Cell-mediated PgD2 Overproduction. Am J Respir Crit Care Med 2019; 200:651.</a></li><li><a class="nounderline abstract_t">Eastman JJ, Cavagnero KJ, Deconde AS, et al. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2017; 140:101.</a></li><li><a class="nounderline abstract_t">Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394:1638.</a></li><li><a class="nounderline abstract_t">Laidlaw TM, Mullol J, Fan C, et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract 2019; 7:2462.</a></li><li><a class="nounderline abstract_t">Mullol J, Laidlaw TM, Bachert C, et al. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. Allergy 2022; 77:1231.</a></li><li><a class="nounderline abstract_t">Bridgewood C, Wittmann M, Macleod T, et al. T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases. J Invest Dermatol 2022; 142:2660.</a></li><li><a class="nounderline abstract_t">Miss Ozuna L, Ryan T, Bensko JC, et al. Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2022; 128:469.</a></li><li><a class="nounderline abstract_t">Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131:110.</a></li><li><a class="nounderline abstract_t">Bobolea I, Barranco P, Fiandor A, et al. Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol 2010; 20:448.</a></li><li><a class="nounderline abstract_t">Bergmann KC, Zuberbier T, Church MK. Omalizumab in the treatment of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2015; 3:459.</a></li><li><a class="nounderline abstract_t">Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021; 9:1141.</a></li></ol></div><div id="topicVersionRevision">Topic 520 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5646829" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Intolerance to aspirin. Clinical studies and consideration of its pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668892" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Natural history and clinical features of aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12452205" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35643277" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pediatric-onset aspirin-exacerbated respiratory disease: Clinical characteristics, prevalence, and response to dupilumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11028656" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31442000" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25282015" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286156" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24980235" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Aspirin hypersensitivity in patients with chronic rhinosinusitis and nasal polyposis: frequency and contributing factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14976098" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10480701" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743549" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743549" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8096945" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Leukotriene E4 and granulocytic infiltration into asthmatic airways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673243" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of aspirin-intolerant asthma with antileukotrienes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23246457" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25218285" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8143059" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12153961" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1309376" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Increased excretion of leukotriene E4 during aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2451458" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10482828" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19482346" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Leukotriene E4: perspective on the forgotten mediator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8564100" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461132" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083703" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Aspirin and asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17584993" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262771" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2826437" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Transcellular metabolism of neutrophil-derived leukotriene A4 by human platelets. A potential cellular source of leukotriene C4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18589840" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668897" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pathogenesis of aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12816731" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466979" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8658372" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7798537" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16583357" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9393345" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10970818" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421891" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10933083" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757457" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30580047" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256883" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928974" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The potent and selective sulfidopeptide leukotriene antagonist, SK&amp;F 104353, inhibits aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8091318" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12704352" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23889565" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10390414" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673176" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743569" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24486071" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22418066" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24085850" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30339852" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16293803" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34364538" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275362" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30376852" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of Zileuton in Patients with Asthma and History of Aspirin Sensitivity: A Retrospective Analysis of Data from Two Phase 3 Studies</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30529603" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hearing loss and middle ear symptoms in aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25858054" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27830335" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30485725" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Patterns of olfactory dysfunction in chronic rhinosinusitis identified by hierarchical cluster analysis and machine learning algorithms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19056109" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30391549" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24607050" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27396680" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37395977" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pathophysiological Link Between Chronic Rhinosinusitis and Ear Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24125137" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Characterization and treatment of patients with chronic rhinosinusitis and nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638784" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Total IgE levels and peripheral eosinophilia: correlation with mucosal disease based on computed tomographic imaging of the paranasal sinus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8283586" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Chronic sinusitis. Relationship of computed tomographic findings to allergy, asthma, and eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580883" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Local and systemic eosinophilia in patients undergoing endoscopic sinus surgery for chronic rhinosinusitis with and without polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580883" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Local and systemic eosinophilia in patients undergoing endoscopic sinus surgery for chronic rhinosinusitis with and without polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16055872" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20128418" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Diagnosis of aspirin-induced asthma combining the bronchial and the oral challenge tests: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112958" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Chronic rhinosinusitis: allergy and sinus computed tomography relationships.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25197914" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25634222" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29777744" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Omalizumab can inhibit respiratory reaction during aspirin desensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28117272" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22763305" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33746062" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17481713" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32077450" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : European Position Paper on Rhinosinusitis and Nasal Polyps 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34174296" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33307116" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma&amp;Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560658" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388008" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779723" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15332389" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563738" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17165280" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of leukotriene modifier drugs on the safety of oral aspirin challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21217919" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Aspirin-exacerbated respiratory disease: evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20674823" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12532116" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18699939" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34543652" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17208597" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26083948" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29552073" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6368649" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2299107" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18589844" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876550" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17181095" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Medical and surgical considerations in patients with Samter's triad.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12669898" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24767875" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25118195" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30978291" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31026400" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Aspirin-exacerbated Respiratory Disease: A Syndrome of Mast Cell-mediated PgD2 Overproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28279492" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31543428" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30954643" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34459002" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35395222" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35124224" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021878" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20945617" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25648572" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Omalizumab in the treatment of aspirin-exacerbated respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33872587" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
